trial · primary record
BI 3810944
Solid Tumours
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 69 |
| Primary completion | 2029-10-05 |
| Primary endpoint | Part A (dose escalation): Occurrence of Cytokine Release Syndrome (CRS) Grade 1 or 2 during the primary Dose Limiting Toxicity (DLT) evaluation period, as a sign of minimal immunological activity that primes the immune system |
| Registry ID | NCT07224425 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:11.971Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07224425
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.